Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,547Inflammatory Bowel DiseasePsoriasis: Treatment and PathogenesisOcular Diseases and Behçet’s Syndrome

The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial

Open access

Abstract

OBJECTIVE: The authors tested whether the anti-interleukin (IL)-17A monoclonal antibody secukinumab was safe and effective for the treatment of active Crohn's disease. DESIGN: In a double-blind, randomised, placebo-controlled proof-of-concept study, 59 patients with moderate to severe Crohn's disease (Crohn's Disease Activity Index (CDAI) ≥220 to ≤450) were assigned in a 2:1 ratio to 2×10 mg/kg intravenous secukinumab or placebo. The primary end point, addressed by bayesian statistics augmented with historical placebo information, was the probability that secukinumab reduces the CDAI by ≥50 points more than placebo at week 6. Ancillary analyses explored associations of 35 candidate genetic polymorphisms and faecal calprotectin response. RESULTS: 59 patients (39 secukinumab, 20 placebo, mean baseline CDAI 307 and 301, respectively) were recruited. 18/59 (31%) patients discontinued prematurely (12/39 (31%) secukinumab, 6/20 (30%) placebo), 10/59 (17%) due to insufficient therapeutic effect (8/39 (21%) secukinumab, 2/20 (10%) placebo). Fourteen serious adverse events occurred in 10 patients (seven secukinumab, three placebo); 20 infections, including four local fungal infections, were seen on secukinumab versus none on placebo. Primary end point analysis estimated <0.1% probability (CDAI (SD) =33.9 (19.7), 95% credible interval -4.9 to 72.9) that secukinumab reduces CDAI by ≥50 points more than placebo. Secondary area under the curve analysis (weeks 4-10) showed a significant difference (mean ΔCDAI=49; 95% CI (2 to 96), p=0.043) in favour of placebo. Post hoc subgroup analysis showed that unfavourable responses on secukinumab were driven by patients with elevated inflammatory markers (CRP≥10 mg/l and/or faecal calprotectin≥200 ng/ml; mean ΔCDAI=62; 95% CI (-1 to 125), p=0.054 in favour of placebo). Absence of the minor allele of tumour necrosis factor-like ligand 1A was strongly associated with lack of response measured by baseline-adjusted changes in calprotectin at week 6 (p=0.00035 Bonferroni-corrected). CONCLUSIONS: Blockade of IL-17A was ineffective and higher rates of adverse events were noted compared with placebo. CLINICAL TRIAL REGISTRATION: This trial was registered at ClinicalTrial.gov with the number NCT01009281.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2011-301668

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Research works printed but not linked: 2

  1. 10.1053/gast.2001.24042 · DOI · Paper page
  2. 10.1002/acr.20420 · doi:10.1002/acr.20420

Cited by

See all 1,547

Metadata

Authors
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., Karczewski, J., Pezous, N., Bek, S., Bruin, G., Mellgard, B., Berger, C., Londei, M., Bertolino, A. P., Tougas, G., Travis, S. P. L., & for the Secukinumab in Crohn's Disease Study Group
Affiliations
  • Novartis Institutes for BioMedical Research (CH)
  • Mount Sinai Hospital (US)
  • Novartis (United States) (US)
  • Novartis (Switzerland) (CH)
  • Medical University of Vienna (AT)
  • University of Michigan (US)
  • Robert Bosch Hospital (DE)
  • Western University (CA)
  • National Institutes of Health (US)
  • Solumed Research Unit, Poznan, Poland
  • Genomics Institute of the Novartis Research Foundation (US)
  • University of Oxford (GB)
Corresponding author
Hueber, Wolfgang
Venue
Gut
Publisher
BMJ
Published
2012-05-17
Volume
61
Issue
12
Pages
1693-1700
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2132784721
Cited by
1,547
References
40
Citations by year
2026: 73 · 2025: 84 · 2024: 87 · 2023: 112 · 2022: 107 · 2021: 137 · 2020: 159 · 2019: 154 · 2018: 126 · 2017: 125 · 2016: 107 · 2015: 103 · 2014: 84 · 2013: 72 · 2012: 15
FWCI
52.81
Type
journal article
Language
en
Open access
Locations
  • Gut (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • Novartis Institutes for BioMedical Research
  • National Institute of Allergy and Infectious Diseases (ZIAAI000903)
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
secukinumab, Crohn's disease, anti-IL-17A monoclonal antibody, IL-17A, CDAI, fecal calprotectin, genetic polymorphism, C-reactive protein, treatment response, adverse events, fungal infection, inflammatory markers, subgroup analysis, treatment discontinuation, inflammatory bowel disease
MeSH terms
Adolescent, Adult, Aged, Anti-Inflammatory Agents, Antibodies, Monoclonal, Bayes Theorem, Crohn Disease, Double-Blind Method, Drug Administration Schedule, Female, Genetic Markers, Humans, Infusions, Intravenous, Male, Middle Aged, Severity of Illness Index, Biomarkers, Treatment Failure, Interleukin-17, Polymorphism, Single Nucleotide, Leukocyte L1 Antigen Complex, Young Adult, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. https://app.cochat.ai/papers/10.1136/gutjnl-2011-301668
The paper
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., Karczewski, J., Pezous, N., Bek, S., Bruin, G., Mellgard, B., Berger, C., Londei, M., Bertolino, A. P., Tougas, G., . . . for the Secukinumab in Crohn's Disease Study Group. (2012). Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. https://doi.org/10.1136/gutjnl-2011-301668

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.